Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 19/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.69 |
| ▸ | CYP8B1 | Q9UNU6 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 0.69 |
| ▸ | FYN | P06241 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.69 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.69 |
| ▸ | TACR1 | P25103 | 1/20 | 0.69 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.69 |
| ▸ | CCR4 | P51679 | 1/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.69 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4152523 | 1.00 | ABCG2 (0.71) | ABCG2CYP3A4ABCB11CYP8B1LMNA | |
| SCHEMBL6812825 | 0.95 | ABCG2 (0.80) | ABCG2CYP3A4ABCB11CYP8B1LMNA | |
| SCHEMBL6752603 | 0.95 | ABCG2 (0.80) | ABCG2CYP3A4ABCB11CYP8B1LMNA | |
| SCHEMBL7456729 | 0.95 | ABCG2 (0.70) | ABCG2CYP3A4ABCB11CYP8B1LMNA | |
| SCHEMBL6752594 | 0.95 | ABCG2 (0.80) | ABCG2CYP3A4ABCB11CYP8B1LMNA | |
| SCHEMBL6752596 | 0.95 | ABCG2 (0.80) | ABCG2CYP3A4ABCB11CYP8B1LMNA | |
| SCHEMBL7456690 | 0.95 | ABCG2 (0.80) | ABCG2CYP3A4ABCB11CYP8B1LMNA | |
| SCHEMBL17739438 | 0.95 | CYP3A4 (0.72) | ABCG2CYP3A4ABCB11CYP8B1LMNA | |
| SCHEMBL9664951 | 0.95 | CYP3A4 (0.72) | ABCG2CYP3A4ABCB11CYP8B1LMNA | |
| SCHEMBL7453478 | 0.93 | ABCG2 (0.68) | ABCG2CYP3A4ABCB11CYP8B1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4916134-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACUETICA N.V. (BE) | 1990-04-10 | — | — | US | claimed |
| US-20090088443-A1 | NOVEL CRYSTALLINE FORMS OF CONAZOLES AND METHODS OF MAKING AND USING THE SAME | REMENAR JULIUS | 2009-04-02 | — | — | US | disclosed |
| US-7446107-B2 | Crystalline forms of conazoles and methods of making and using the same | TRANSFORM PHARMACEUTICALS, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-20070293674-A1 | Novel Saperconazole Crystalline Forms and Related Processes, Pharmaceutical Compositions and Methods | TRANSFORM PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-7078526-B2 | CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods | TRANSFORM PHARMACEUTICALS, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| US-20050070551-A1 | Novel crystalline forms of conazoles and methods of making and using the same | TRANSFORM PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20040019211-A1 | Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-01-29 | — | — | US | disclosed |
| US-4916134-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACUETICA N.V. (BE) | 1990-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070551-A1 | Novel crystalline forms of conazoles and methods of making and using the same | CYP51A1, CYP3A5, ERG28 | ABCG2 115/4885CYP3A4 10/4885ABCB11 1103/4885 |
| US-20070293674-A1 | Novel Saperconazole Crystalline Forms and Related Processes, Pharmaceutical Compositions and Methods | CYP51A1, CYP3A5, CYP3A43 | ABCG2 87/4885CYP3A4 4/4885ABCB11 413/4885 |
| US-20090088443-A1 | NOVEL CRYSTALLINE FORMS OF CONAZOLES AND METHODS OF MAKING AND USING THE SAME | CYP51A1, CYP3A5, ERG28 | ABCG2 115/4885CYP3A4 10/4885ABCB11 1103/4885 |
| US-20040019211-A1 | Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods | CYP51A1, CYP3A5, CYP3A43 | ABCG2 80/4885CYP3A4 6/4885ABCB11 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.